Photo credit: press service of the Russian Direct Investment Fund
The results of clinical trials of another coronavirus vaccine have been summed up. The drug was created by specialists from the Vector Center, RIA Novosti reports. The vaccine made on the basis of peptide antigens was named EpiVacCorona.
According to Anna Popova, head of Rospotrebnadzor, vaccination against coronavirus will take place on a voluntary basis. But it can become a necessity when it comes to professional risks.
The representative of the Vector Center Alexander Ryzhikov noted that testing proved the safety of the drug. Although the vaccine does not confer lifelong immunity from COVID-19, it protects against infection for at least six months.
Registration of the new vaccine has already begun and will be completed in two weeks. The testing on volunteers will start after that. Placebo-controlled post-registration studies will also be conducted, 5,000 people are going to take part in them.
Scientists noted that materials with test results would appear in Russian and foreign publications in the coming months. EpiVacKorona will be produced at the Vector site; two versions of it are planned to be released into civil circulation.
Russkiy Mir
